Bangladesh Device Vigilance: Ten Working Days Versus the GVP Fifteen and Thirty Days

1. Key takeaways

Bangladesh runs two vigilance clocks side by side, and a device company has to know which one applies to its file. Under the GVP (Good Pharmacovigilance Practice) guideline Version 01, effective September 2023, a serious adverse event must be reported immediately and in any case no later than 15 calendar days, while a non-serious event is reported within 30 calendar days. Under §5 of the DGDA Medical Device Registration Guideline, a medical device vigilance report is submitted within 10 working days from the date the incident becomes known. Devices follow the latter. The two regimes differ both in the unit of counting and in the point at which counting starts, and the difference is not cosmetic.

• Device reports follow the 10 working days rule in §5 of the registration guideline, counted from the date of knowledge.
• The GVP figures of 15 calendar days for serious and 30 calendar days for non-serious events belong to the pharmacovigilance regime, not to device files.
• Calendar days and working days are different units: ten working days spans roughly two calendar weeks, while fifteen calendar days is fixed at two weeks.
• The GVP requires a QPPV located in Bangladesh, a requirement that in practice lands on the local licence holder.
• The national pharmacovigilance guideline issued by DGDA on 15 August 2018 already covered medical devices in its scope, together with vaccines, biological products, blood products and herbal and traditional complementary medicines.
• Device vigilance is therefore not an obligation created in 2023; the 2023 instrument added timing rules to a framework that had included devices since 2018.

2. Legal basis

The two clocks come from two instruments with different scopes. The table below sets them out in parallel so that the applicable figure can be identified without ambiguity, and so that the background material is not mistaken for an operating standard.

Reading the two instruments together produces a layered picture. The pharmacovigilance guideline supplies the general architecture: who must be appointed, what counts as a reportable event, and what the outer limits are for serious and non-serious cases. The registration guideline supplies the device-specific rule, and because a device-specific provision exists, the device figure is the one that governs a device file. The 2018 national guideline matters for a different reason: it establishes that devices were inside the national vigilance system well before the 2023 timing rules were issued, which removes any argument that the device obligation is a recent addition with no institutional history behind it.

3. Expert insights

Insight one: three documents, three sets of numbers, and device companies must anchor on §5. The GVP gives fifteen days and thirty days; §5 of the registration guideline gives ten working days. Because a dedicated device provision exists, a device project should execute against ten working days. The GVP numbers are frequently misapplied in a device context. The common statement in Chinese-language material that adverse events in Bangladesh are reported within fifteen days is, in most instances, the GVP figure applied to a device file without checking whether a device-specific rule exists.

Insight two: calendar days and working days are two different units, and the difference runs in both directions. The GVP counts calendar days; §5 counts working days. Ten working days covers roughly two weeks of calendar time once weekends are excluded, while fifteen calendar days is fixed at two weeks regardless of holidays. Confusing the units can make a team report early or late, and both outcomes carry compliance consequences: an early report filed before the analysis is complete creates a deficient file, and a late report is a missed deadline whatever the reason.

Insight three: the 2018 national guideline wrote devices into the system, and that is the institutional basis for device vigilance. WHO records show that the National Guideline on Pharmacovigilance System of Bangladesh, issued by DGDA on 15 August 2018, explicitly includes medical devices within its scope. That dating matters in a dispute about applicability. It shows that device vigilance was not a new obligation introduced in 2023; devices were brought into the national vigilance system in 2018, and the later instruments built on that foundation rather than creating it.

Insight four: the QPPV residency requirement lands on the licence holder. The GVP requires the appointment of a QPPV located within Bangladesh. For an overseas manufacturer, that post is normally filled by the local licence holder. This is a substantive obligation to negotiate when selecting a licence holder, not a nominal signature on an organisation chart. The person concerned has to be reachable, has to hold the relevant records, and has to be in a position to act when a clock starts, which means the arrangement needs to be written into the agreement with a named role, a defined scope and a cost allocation.

Insight five: the coexistence of the two regimes is a documentation risk, not a legal ambiguity. Nothing in the two instruments is contradictory once their scopes are separated. The risk arises inside companies, where a pharmacovigilance SOP written for a pharmaceutical portfolio is applied to a device portfolio because nobody revised the SOP when the device line was added. The result is a file that cites fifteen days in its own procedure and is assessed against ten working days, which is difficult to defend even where the actual reporting was timely.

4. Practical recommendations

• Adopt a single timing standard in the device vigilance SOP: 10 working days from the date of knowledge, per §5 of the registration guideline.
• Annotate the GVP figures of 15 and 30 calendar days as background in a footnote to the procedure, and state explicitly that they are not the operating standard for devices, so that staff do not import them at the point of use.
• Specify in the agreement with the local licence holder who fills the QPPV role, what the role covers, and who bears the cost, given that the post must be located in Bangladesh.
• Run a vigilance drill every quarter, with the objective of turning the act of registering the knowledge date into a reflex rather than a decision.
• Keep the 2018 national guideline in the reference set for the file, so that the applicability of device vigilance can be demonstrated from the source rather than asserted.
• Review the SOP whenever the portfolio mixes devices with medicinal products, because that is where the two clocks are most likely to be confused.

5. Verification checklist

• □ Device vigilance has adopted the 10 working days standard in §5 of the guideline
• □ The counting unit is working days, and it is distinguished from calendar days in the procedure
• □ The GVP figures of 15 and 30 calendar days appear only as annotation, not as the operating standard
• □ The QPPV responsibility has been allocated in the agreement, with the post located in Bangladesh
• □ The team is aware that the 2018 national vigilance guideline brought devices into scope
• □ A quarterly vigilance drill is scheduled in the compliance calendar
• □ No pharmacovigilance SOP written for medicinal products is being applied to the device portfolio without revision

Regulatory information verified as at 27 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across South Asia, including Bangladesh. Our team prepares dossiers to DGDA expectations, manages submissions and deficiency responses, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com